



Docket: PP01573.101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Derek O'Hagan et al.  
Application No.: 09/914,279  
Date Filed: 01/09/2002  
Title: MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND  
MICROMOLECULES  
Group Art Unit: 1615  
Examiner: Carlos A. Azpuru  
Atty. Docket No.: PP01573.101

INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

JUN 30 2004

TECH CENTER 1600/2900

SIR:

In accordance with 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §§1.97 and 1.98, the references listed on attached Form PTO/SB/08 and/or subsequently identified herein, are being submitted herewith for consideration by the United States Patent and Trademark Office.

I. COPIES

- a. ☒ A legible copy of (i) each U.S. and foreign patents; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed, is included herewith.
- b. ☐ Any patents, publications or other information which are listed on PTO/SB/08 which are not enclosed herewith were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. §120:

U.S. Serial Number

U.S. Filing Date

II. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

- a. ☒ Except as may be indicated below in (b) of this section, all of the patents, publications or other information are in the English language (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. ☐ The following additional information is provided for the Examiner's consideration:

III. ☐ CROSS REFERENCE TO RELATED APPLICATION(S)

The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this (these) applications to the Examiner's attention, Applicant(s) does(do) not waive the confidentiality provisions of 35 U.S.C. §122.

Serial No.

Filing Date

Art Unit

06/24/2004 GWORDF1 00000057 501047 09914279

02 FC:1806 180.00 DA


**FEES**

- IV. ☐ **THIS IDS IS BEING FILED UNDER 37 C.F.R. §1.97(b):** (check one box)
- a. ☐ within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) (37 C.F.R. §1.97(b)(1)). No fee or statement is required.
  - b. ☐ within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. §1.97(b)(2)). No fee or statement is required.
  - c. ☐ before the mailing date of a first Office Action on the merits (37 C.F.R. §1.97(b)(3)). No fee or statement is required.
  - d. ☐ before the mailing date of a first Office Action after the filing of a request for continued examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
- V. ☒ **THIS IDS IS BEING FILED UNDER 37 C.F.R. §1.97(c):** (check one box)
- before the mailing date of any of a Final Office Action under 37 C.F.R. §1.113, a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (See 37 C.F.R. §1.97(c)).
- a. ☒ No statement; therefore, charge deposit account 50-1047 the fee set forth in 37 C.F.R. §1.17(p).
  - b. ☐ See the statement below. No fee is required.
- VI. ☐ **THIS IDS IS BEING FILED UNDER 37 C.F.R. §1.97(d):**
- on or before payment of the issue fee and is accompanied by the following:
- 1) a statement under 37 C.F.R. §1.97(e) as provided below; and
  - 2) charge deposit account 50-1047 the petition fee set forth in §1.17(p).
- VII. ☐ **STATEMENT UNDER 37 C.F.R. §1.97(e)** (check only one box, if applicable)
- The undersigned hereby states that
- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of IDS; or
  - b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and to knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement, or
  - c. ☐ some of the items of information contained in the IDS were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.
- VIII. **PAYMENT OF FEES**
- ☐ A check in the amount of \_\_\_\_\_ is enclosed for the above-identified fee(s).
  - ☒ Please charge Deposit Account No. 50-1047 in the amount of \$180.00 for the above-indicated fee(s).
  - ☒ If Applicant has overlooked any additional fees, or if any overpayment has been made, the Commissioner is hereby authorized to credit or debit Deposit Account 50-1047.
  - ☐ Two Copies of this paper are attached for Deposit Account charges and debits.

It is Applicant(s)' opinion that the claims presently on file patentably distinguish the present invention from each of these references. The above references are being cited only in the interests of candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in a combination, to a person of ordinary skill in the art.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 50-1047.

Respectfully submitted,



David B. Bonham  
Attorney for Applicant(s)  
Reg. No. 34,297  
Tel. 703-433-0510  
Fax: 703-433-2362

MAYER FORTKORT & WILLIAMS  
Customer Number 27774

Enclosures: ☒ PTO/SB/08  
☒ References  
☐ Foreign Search Report  
☐ Other:

Certificate of Mailing by First Class Mail


I certify that this document and fee is being deposited

6/17/04

with the U.S. Postal Service as first class mail

under 37 C.F.R. 1.8 and is addressed to Mail Stop Fee Amendment,

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
\_\_\_\_\_  
Signature of Person Mailing Correspondence

Marjorie Scariati  
\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

A circular ink stamp from the Patent &amp; Trademark Office. The text "PATENT &amp; TRADEMARK OFFICE" is curved along the bottom inner edge. The date "JUN 21 2004" is stamped in the center. The number "168" is curved along the top inner edge.

Please type a plus sign (+) inside this box. FORM PTO/SB/08

**TECH CENTER 1600/2900**

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	09/914,279
				Filing Date	01/09/2002
				First Named Inventor	Derek O'Hagan et al.
				Group Art Unit	1615
				Examiner Name	Carlos A. Azpuru
Sheet	1	of	2	Attorney Docket Number	PP01573.101

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> Unique citation designation number. <sup>2</sup> See Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English Language Translation is attached.



JUN 30 2004

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box. FORM PTO/SB/08

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/914,279		
		Filing Date	01/09/2002		
		First Named Inventor	Derek O'Hagan et al.		
		Group Art Unit	1615		
		Examiner Name	Carlos A. Azpuru		
Sheet	2	of	2	Attorney Docket Number	PP01573.101

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1.	Manmohan Singh et al., "Cationic Microparticles: A Potent Delivery System for DNA Vaccines," <i>Proceedings of the National Academy of Science USA</i> , Vol. 97, no. 2, Jan. 18, 2000, pp. 811-816.	
	2.	Feng Liu et al., "Effect of Non-Ionic Surfactants on the Formation of DNA/Emulsion Complexes and Emulsion-Mediated Gene Transfer," <i>Pharmaceutical Research</i> , Vol. 13, no. 11, 1996, pp. 1642-1646.	
	3.	Toshifumi Hara et al., "In vivo Gene Delivery to the Liver Using Reconstituted Chylomicron Remnants as a Novel Nonviral Vector," <i>Proceedings of the National Academy of Sciences USA</i> , Vol. 94, Dec. 1997, pp. 14547-14552.	
	4.	F. Brunel et al., "Cationic Lipid DC-Chol Induces an Improved and Balanced Immunity Able to Overcome the Unresponsiveness to the Hepatitis B Vaccine," <i>Vaccine</i> , Vol. 17, 1999, pp. 2192-2203.	
	5.	Elias Fattal et al., "Biodegradable Polyalkylcyanoacrylate Nanoparticles for the Delivery of Oligonucleotides," <i>Journal of Controlled Release</i> , Vol. 53, 1998, pp. 137-143.	

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation, if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.